Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Evotec SE buy FXX

Start price
€25.50
29.11.20 / 50%
Target price
-
29.11.21
Performance (%)
20.04%
End price
€30.61
24.03.21
Summary
This prediction ended on 24.03.21 with a price of €30.61. The BUY prediction by FXX finished with a performance of 20.04%. FXX has 50% into this prediction

Evotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.

Performance without dividends (%)
Name 1w 1m 1y 3y
Evotec SE 0.000% 0.000% -23.055% -59.670%
iShares Core DAX® 0.160% -1.640% 12.016% 15.557%
iShares Nasdaq 100 -3.020% -4.715% 37.102% 42.685%
iShares Nikkei 225® -2.519% -7.621% 18.066% 2.904%
iShares S&P 500 -1.377% -2.809% 26.536% 41.689%

According to FXX what are the pros and cons of Evotec SE for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
High dividend yield expected
positive Cash Flow expected
Good rating
Standard Investments for future growth
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Top 10 in its market
Very small cyclical dependencies
Known brand
Future proof or reliable business model
Cons
Risky balance sheet
Few uniques

Comments by FXX for this prediction

In the thread Evotec AG diskutieren

Buy Evotec AG

In the thread Trading Evotec AG
Prediction Buy
Perf. (%) 20.04%
Target price
Change
Ends at 29.11.21

Buy beendet

Stopped prediction by FXX for Evotec SE

buy
Evotec SE

Start price
Target price
Perf. (%)
€20.35
08.12.19
-
13.12.19
4.67%
13.12.19

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation